vitamin-k-semiquinone-radical and Peripheral-Nervous-System-Diseases

vitamin-k-semiquinone-radical has been researched along with Peripheral-Nervous-System-Diseases* in 5 studies

Reviews

1 review(s) available for vitamin-k-semiquinone-radical and Peripheral-Nervous-System-Diseases

ArticleYear
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fi
    Circulation. Cardiovascular quality and outcomes, 2017, Volume: 10, Issue:5

    Topics: Administration, Oral; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Humans; Multicenter Studies as Topic; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Vitamin K; Warfarin

2017

Other Studies

4 other study(ies) available for vitamin-k-semiquinone-radical and Peripheral-Nervous-System-Diseases

ArticleYear
Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes.
    PloS one, 2020, Volume: 15, Issue:2

    Diabetic peripheral neuropathy is a frequent and severe complication of diabetes. As Matrix-gla-protein (MGP) is expressed in several components of the nervous system and is involved in some neurological disease, MGP could play a role in peripheral nervous system homeostasis. The aim of this study was to evaluate factors associated with sensitive diabetic neuropathy in Type 2 Diabetes, and, in particular, dephospho-uncarboxylated MGP (dp-ucMGP), the inactive form of MGP.. 198 patients with Type 2 Diabetes were included. Presence of sensitive diabetic neuropathy was defined by a neuropathy disability score (NDS) ≥6. Plasma levels of dp-ucMGP were measured by ELISA.. In this cohort, the mean age was 64+/-8.4 years old, and 80% of patients were men. Peripheral neuropathy was present in 15.7% of the patients and was significantly associated (r = 0.51, p<0.0001) with dp-ucMGP levels (β = -0.26, p = 0.045) after integrating effects of height (β = -0.38, p = 0.01), insulin treatment (β = 0.42, p = 0.002), retinopathy treated by laser (β = 0.26, p = 0.02), and total cholesterol levels (β = 0.3, p = 0.03) by multivariable analysis.. The association between diabetic neuropathy and the inactive form of MGP suggests the existence of new pathophysiological pathways to explore. Further studies are needed to determine if dp-ucMGP may be used as a biomarker of sensitive neuropathy. Since dp-ucMGP is a marker of poor vitamin K status, clinical studies are warranted to explore the potential protective effect of high vitamin K intake on diabetic peripheral neuropathy.

    Topics: Aged; Biomarkers; Calcium-Binding Proteins; Cohort Studies; Diabetes Mellitus, Type 2; Extracellular Matrix Proteins; Female; Humans; Male; Matrix Gla Protein; Middle Aged; Peripheral Nervous System Diseases; Risk Factors; Vitamin K

2020
Iliacus haematoma syndrome as a complication of anticoagulant therapy.
    British medical journal, 1968, Oct-12, Volume: 4, Issue:5623

    Topics: Aged; Bronchitis; Femoral Nerve; Hematoma; Humans; Hypertension; Male; Peripheral Nervous System Diseases; Phenindione; Tetracycline; Thrombophlebitis; Vitamin K

1968
MALABSORPTION SYNDROME AND PERIPHERAL NEUROPATHY. REPORT OF TWO CASES.
    Cleveland Clinic quarterly, 1964, Volume: 31

    Topics: Celiac Disease; Crohn Disease; Diet; Diet Therapy; Enteritis; Glutens; Humans; Malabsorption Syndromes; Neuritis; Peripheral Nervous System Diseases; Sprue, Tropical; Vitamin B 12; Vitamin B Complex; Vitamin D; Vitamin K; Vitamins

1964
[TREATMENT OF PERIPHERAL NERVE PARALYSIS (THE EFFECT OF DRUGS ON THE HEALING PROCESS)].
    Nihon Seikeigeka Gakkai zasshi, 1964, Volume: 38

    Topics: Animals; Cytochromes; Electromyography; Paralysis; Peripheral Nervous System Diseases; Pharmacology; Rabbits; Research; Vasodilator Agents; Vitamin A; Vitamin K; Vitamins

1964